Key result
Pharmacogenetic-guided coumarin therapy shows potential to reduce bleeding risk.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Greaves discusses a new study in PLoS Medicine that takes us closer to being able to adopt a pharmacogenetic approach to reduce bleeding risk from coumarin therapy.
No takes yet. Share an insight, caveat, or question.
M. Greaves (2005) studied this question. Pharmacogenetic approaches to coumarin anticoagulant therapy show potential for reducing patient bleeding risk.
Synapse has enriched 10 related papers. Consider them for comparative context: